Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
March 24, 2026
Foley Viewpoints
Alamo Title Company v. WFG National Title Company of Texas, LLC: Texas Business Court Takes Broad View of Jurisdiction in Ruling on Motion to Remand
The Court held that the statute granting jurisdiction should be interpreted according to its plain language, requiring only that the controversy be “related to” intellectual property, a phrase Texas courts have consistently construed broadly. The Court also provided guidance on how the amount in controversy requirement should be interpreted.
March 24, 2026
Foley Viewpoints
NAIC Spring 2026 Meeting: Third-Party Data and Models (H) Working Group – March 23, 2026
Summary and Takeaways: The Third-Party Data and Models (H) Working Group continues to move its Third Party Regulatory Framework…
March 24, 2026
Blogs
False Claims Act Enforcement in 2026
The US Department of Justice (DOJ) reported a record year for False Claims Act (FCA) enforcement in fiscal year 2025, with more than $6.8 billion in settlements and judgments — the largest annual total in the history of the statute.